Formycon Affirms Full-Year Outlook After Strategic Developments

Formycon AG has announced its confidence in achieving its full-year 2025 guidance following key developments. The company's interim results meet expectations, confirming the revenue forecast at €55.0 to €65.0 million for 2025. In July, Formycon placed a €70 million corporate bond to bolster working capital, raising the outlook to €55.0 to €65.0 million.

The biosimilar FYB202's market penetration and the FYB206 partnership are anticipated to drive growth. The half-year revenue was €9.0 million, reflecting strategic shifts and reduced one-off revenue compared to the prior year. EBITDA is projected between €-20.0 million and €-10.0 million, unchanged from previous guidance.

Operational advancements include the successful enrollment for the FYB206 Phase I trial. The company's strategic positioning supports long-term growth, with projections for a steady performance trajectory into 2026-2027.